These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35507486)

  • 21. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
    King B; Ko J; Forman S; Ohyama M; Mesinkovska N; Yu G; McCollam J; Gamalo M; Janes J; Edson-Heredia E; Holzwarth K; Dutronc Y
    J Am Acad Dermatol; 2021 Oct; 85(4):847-853. PubMed ID: 34090959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.
    Rubin R
    JAMA; 2022 Jun; 327(23):2281. PubMed ID: 35727290
    [No Abstract]   [Full Text] [Related]  

  • 23. Atopic dermatitis and multilocular alopecia areata simultaneously treated with baricitinib.
    Pestana M; Brito Caldeira M; Duarte B
    Actas Dermosifiliogr; 2024 Feb; 115(2):T200-T201. PubMed ID: 37952837
    [No Abstract]   [Full Text] [Related]  

  • 24. Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib.
    Pestana M; Brito Caldeira M; Duarte B
    Actas Dermosifiliogr; 2024 Feb; 115(2):200-201. PubMed ID: 36842474
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis.
    Guan R; Lin Y; Zhang C; Wang Z; Wu Z; Liu X; Chen X; Piao Y
    Arch Dermatol Res; 2024 Jul; 316(7):483. PubMed ID: 39042154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and safety of baricitinib in patients with moderate-to-severe refractory alopecia areata in real world: An open-label, single-center study.
    Bi L; Wang C; Du Y; Su T; Zhao M; Lin X; Fan W; Sun W
    J Cosmet Dermatol; 2024 Apr; 23(4):1417-1421. PubMed ID: 38116864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
    Melikhov O; Kruglova T; Lytkina K; Melkonyan G; Prokhorovich E; Putsman G; Rodoman G; Vertkin A; Zagrebneva A; Stebbing J
    Ann Rheum Dis; 2021 Sep; 80(9):1245-1246. PubMed ID: 34099486
    [No Abstract]   [Full Text] [Related]  

  • 28. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
    Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
    Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
    Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients.
    Numata T; Irisawa R; Mori M; Uchiyama M; Harada K
    Acta Derm Venereol; 2024 Jan; 104():adv18348. PubMed ID: 38248913
    [No Abstract]   [Full Text] [Related]  

  • 31. Baricitinib as the first systemic treatment for severe alopecia areata.
    Kincaid CM; Arnold JD; Mesinkovska NA
    Expert Rev Clin Immunol; 2023 Jun; 19(6):565-573. PubMed ID: 37042112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
    Senna M; Mostaghimi A; Ohyama M; Sinclair R; Dutronc Y; Wu WS; Yu G; Chiasserini C; Somani N; Holzwarth K; King B
    J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):583-593. PubMed ID: 38391212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
    Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
    Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baricitinib (Olumiant) for the Treatment of Alopecia Areata.
    Pheasant L
    Am Fam Physician; 2023 Nov; 108(5):513-514. PubMed ID: 37983706
    [No Abstract]   [Full Text] [Related]  

  • 36. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
    Jabbari A; Dai Z; Xing L; Cerise JE; Ramot Y; Berkun Y; Sanchez GA; Goldbach-Mansky R; Christiano AM; Clynes R; Zlotogorski A
    EBioMedicine; 2015 Apr; 2(4):351-5. PubMed ID: 26137574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Good and Bad News About New Drugs for Treating Alopecia Areata.
    Morgado-Carrasco D; Rodríguez-Lobato E; Riera-Monroig J; Ferrando J
    Actas Dermosifiliogr (Engl Ed); 2018; 109(1):69-70. PubMed ID: 28641742
    [No Abstract]   [Full Text] [Related]  

  • 39. Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children.
    Fang H; Zhang F; Lin W; Jiang Y; Liu Q; Yang D
    Front Immunol; 2024; 15():1395288. PubMed ID: 38903518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective treatment of oral lichen planus with the JAK inhibitor baricitinib.
    Moussa A; Colla T; Morrison B; Sinclair R
    Australas J Dermatol; 2022 May; 63(2):276-277. PubMed ID: 35213737
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.